Utility of a Patient-Reported Symptom and Functioning Assessment Tool for Geriatric Oncology Care in China.
Study Goal
The researchers aimed to evaluate the reliability and validity of the MD Anderson Symptom Inventory (MDASI) for assessing symptom burden and functional status, including walking interference, in older Chinese cancer patients.
Results Summary
The study found that moderate to severe interference with walking on the MDASI accurately indicated poor performance status and lack of independence in Activities of Daily Living, with an area under the curve of 0.7969 and 0.8304, respectively.
Population
Chinese patients with cancer aged 65 years and older (n = 779, divided into younger [65-74 years] and older [75-84 years] groups).
Effective Dosage
Not available
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
MD Anderson Symptom Inventory (MDASI) | no change | symptom burden and functional status | Chinese patients with cancer aged 65 years and older | - | is psychometrically reliable, valid, and clinically sensitive for the measuring | #1 |
MD Anderson Symptom Inventory (MDASI) | no change | multiple symptoms and physical functioning outcomes | geriatric oncology practice | - | could be adopted to measure | #2 |
MD Anderson Symptom Inventory (MDASI) | no change | treatment benefits | - | - | could be adopted for research on | #3 |
- | increase | difficulty remembering | older group (75-84 years old) | effect size 0.32 | reported a more severe | #4 |
- | increase | shortness of breath | older group (75-84 years old) | effect size 0.20 | reported a more severe | #5 |
- | increase | interference with general activity | older group (75-84 years old) | effect size 0.14 | reported a more severe | #6 |
- | decrease | physical functioning | older group (75-84 years old) | effect size -0.33 | with significantly worse | #7 |
- | decrease | cognitive functioning | older group (75-84 years old) | effect size 0.20 | with significantly worse | #8 |
MDASI measures of the core symptoms | no change | reliability | younger group (65-74 years old) | 0.90 | Cronbach α coefficients were | #9 |
MDASI measures of total interference with daily activity | no change | reliability | younger group (65-74 years old) | 0.93 | Cronbach α coefficients were | #10 |
MDASI measures of the core symptoms | no change | reliability | older group (75-84 years old) | 0.93 | Cronbach α coefficients were | #11 |
MDASI measures of total interference with daily activity | no change | reliability | older group (75-84 years old) | 0.94 | Cronbach α coefficients were | #12 |
MDASI moderate to severe interference with general activity | no change | poor performance status | - | area under the curve 0.8089 | accurately indicated | #13 |
MDASI moderate to severe interference with walking | no change | poor performance status | - | area under the curve 0.7969 | accurately indicated | #14 |
MDASI moderate to severe interference with general activity | no change | lack of independence status of Activities of Daily Living | - | area under the curve 0.7993 | accurately indicated | #15 |
MDASI moderate to severe interference with walking | no change | lack of independence status of Activities of Daily Living | - | area under the curve 0.8304 | accurately indicated | #16 |
OBJECTIVES: Symptom and functional assessment is challenging in geriatric oncology care. This multicenter cross-sectional study examined the use of a multiple-symptom assessment tool, the MD Anderson Symptom Inventory (MDASI), on Chinese patients with cancer aged 65 years and older. METHODS: Patient-rated symptoms and functioning were assessed using MDASI and the European Organization for Research and Treatment of Cancer quality-of-life questionnaire. RESULTS: The most severe symptoms were fatigue and poor appetite. The older group (75-84 years old, n = 224) reported a more severe difficulty remembering (effect size [ES] 0.32; P < .001), shortness of breath (ES 0.20; P = .020), and interference with general activity (ES 0.14; P = .027), with significantly worse physical functioning (ES -0.33; P < .001) and cognitive functioning on the European Organization for Research and Treatment of Cancer quality-of-life questionnaire (ES 0.20; P < .001) than the younger group (65-74 years old, n = 555). For MDASI measures of the core symptoms and total interference with daily activity, Cronbach α coefficients were 0.90 and 0.93, respectively, for the younger group; and 0.93 and 0.94 for the older group, respectively. Moderate to severe (score ≥4) interference with general activity and walking on MDASI accurately indicated poor performance status (area under the curve 0.8089 and 0.7969, respectively) and lack of independence status of Activities of Daily Living (area under the curve 0.7993 and 0.8304, respectively). CONCLUSIONS: MDASI is psychometrically reliable, valid, and clinically sensitive for the measuring symptom burden and functional status of Chinese patients with cancer aged 65 years and older. MDASI could be adopted to measure multiple symptoms and physical functioning outcomes in geriatric oncology practice as well as for research on treatment benefits.